CARLOS MANUEL
PANIZO SANTOS
Hospital San Pedro
Logroño, EspañaPublicaciones en colaboración con investigadores/as de Hospital San Pedro (10)
2020
-
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073
-
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
British Journal of Haematology, Vol. 188, Núm. 5, pp. 661-673
2019
2018
-
Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia
Immunotherapy, Vol. 10, Núm. 6, pp. 491-499
-
Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73
2017
-
First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study
European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43
-
Follicular lymphoma (FL): Immunological tolerance theory in FL
Human Immunology, Vol. 78, Núm. 2, pp. 138-145
2016
-
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity
Immunologic Research, Vol. 64, Núm. 2, pp. 548-557
-
Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics
Nature Communications, Vol. 7
2014
-
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab
Annals of Hematology, Vol. 93, Núm. 11, pp. 1879-1887